Genetic Profiles of 120 Atopic Dermatitis Patients and Dupilumab Response

120 patients with moderate-to-severe atopic dermatitis treated with Dupilumab were enrolled at two Italian centers. Clinical and genetic data were collected at baseline and after 48 weeks, with genotyping of 521 SNPs performed via next-generation sequencing. The study by Martina Morelli, last updated in April 2026, identified genetic signatures associated with clinical phenotypes and therapy response.

Use Cases

• Predicting Dupilumab therapy response based on genetic variants like FLG rs749682384 and IL6R rs2228145
• Clustering patients into genetic subgroups based on polymorphisms in skin barrier genes FLG and KIF3A
• Investigating associations between specific SNPs and comorbidities like conjunctivitis, rhinitis, and bronchial asthma
• Identifying genetic markers associated with generalized eczema phenotype from combined KIF3A and FLG variant patterns

Strengths

• Includes 120 patient records with clinical and genetic data
• Contains genotyping results for 521 SNPs
• Clinical data collected at baseline and after 48 weeks of treatment

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data may reflect geographic bias inherent to the two Italian centers

Provenance

Source

Martina Morelli

Collection Method

Clinical data collection and next-generation sequencing genotyping of 521 SNPs

Time Range

Clinical data collected at baseline and after 48 weeks of treatment

Freshness

Last updated 2026-04-10 06:03:25; freshness should be verified

Geography

Two Italian centers